Aravis

Aravis is a Switzerland based venture capital organisation managing two funds focused on life science (Aravis Biotech I & II) and a third fund focused on renewable energy (Aravis Energy I). Since 1995 the Aravis management team have invested over $600 million in more than 80 companies.

As well as providing venture capital backing, Aravis also takes a hands-on approach to highly promising companies offering a unique international network that combines decades of experience in science, operations and financing.

With a disciplined investment process and Aravis' hands on approach in supporting management, the companies that Aravis has invested in have shown a comparatively low failure rate and many have grown to become some of the leading companies in their fields.

News

01.02.10

 

Synosia Announces Positive Interim Results for Potential First-in-Class Treatment for Parkinson's Disease

...
04.01.10

Evolva enters discovery collaboration with Roche

...
14.12.09

Aravis leads Series B financing in Evolva SA Totalling CHF 44 M (USD 43 M)
followed by a reverse merger of Evolva with Arpida Ltd
Evolva Holding SA then Lists on SIX Swiss Exchange

...
14.12.09
Evolva raises additional CHF 21 million
Evolva SA completes merger with Arpida Ltd
Listing on SIX Swiss Exchange under name Evolva Holding SA ...
02.12.09
S*BIO novel oral JAK2 inhibitor SB1518 demonstrates safety and tolerability in Phase 1 studies for the treatment of Myeloproliferative and other hematological disorders ...
© 2008 Aravis SA  |  Lehfrauenweg 10   |  CH 8053 Zuerich  |  Tel. +41 43 499 20 00 | Fax +41 43 499 20 01  |  Disclaimer  |   Developed by Dogbytes Websolutions